ESMO

Triplet Targeted Therapy Regimen Improves Survival in BRAF+ Metastatic Colorectal Cancer
October 03, 2019

A new combination may be key to improving tumor response rates and overall survival in colorectal cancer.

Apalutamide Survival Benefits Unclear for Castration-Resistant Prostate Cancer
October 03, 2019

Despite prolonged progression-free duration, a 25% reduction in risk of death associated with anti-androgen agent apalutamide fell short of statistical significance in patients with non-metastatic, high-risk castration-resistant prostate cancer.

Targeted Therapy Delays Progression in Advanced Prostate Cancer
October 01, 2019

The findings of a trial presented at ESMO 2019 may be a breakthrough when it comes to molecularly targeted treatment for prostate cancer.